Editorial: The glutamate hypothesis of mood disorders: Neuroplasticity processes, clinical features, treatment perspectives.

Front Psychiatry

Psychiatry Research Unit, Fribourg Network for Mental Health (RFSM), University of Fribourg, Fribourg, Switzerland.

Published: November 2022

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745306PMC
http://dx.doi.org/10.3389/fpsyt.2022.1054887DOI Listing

Publication Analysis

Top Keywords

editorial glutamate
4
glutamate hypothesis
4
hypothesis mood
4
mood disorders
4
disorders neuroplasticity
4
neuroplasticity processes
4
processes clinical
4
clinical features
4
features treatment
4
treatment perspectives
4

Similar Publications

Transcriptomic analysis of the inhibition mechanisms against by antibacterial aptamer B4.

Front Vet Sci

December 2024

State Key Laboratory of Mariculture Breeding, Engineering Research Centre of the Modern Technology for Eel Industry, Ministry of Education, Fisheries College of Jimei University, Xiamen, China.

is a common bacterial pathogen in aquaculture, often leading to visceral white spot disease in large yellow croakers (). Previous studies have found that certain aptamers show an efficient antibacterial effect against this pathogen. In this study, we analyzed the transcriptome of to get insights into the antibacterial and inhibitions mechanisms following exposure to the aptamer B4.

View Article and Find Full Text PDF

Searching for new drugs to treat Alzheimer's disease dementia through multiple pathways.

World J Clin Cases

January 2025

Department of Neurology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China.

Dementia is a group of diseases, including Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, metabolic dementia and toxic dementia. The treatment of dementia mainly includes symptomatic treatment by controlling the primary disease and accompanying symptoms, nutritional support therapy for repairing nerve cells, psychological auxiliary treatment, and treatment that improves cognitive function through drugs. Among them, drug therapy to improve cognitive function is important.

View Article and Find Full Text PDF

MDMA and MDMA-Assisted Therapy.

Am J Psychiatry

January 2025

Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Departments of Psychiatry (Wolfgang) and Medical and Clinical Psychology (Gray), Uniformed Services University, Bethesda, MD; Departments of Psychiatry (Wolfgang, Krystal), Neuroscience (Krystal), and Psychology (Krystal), Yale University School of Medicine, New Haven, CT; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin Dell Medical School (Fonzo, Nemeroff); Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, UCLA (Grzenda); Department of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis (Widge); Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham (Kraguljac); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (McDonald); Department of Psychiatry and Behavioral Sciences, Stanford University and Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (Rodriguez).

Article Synopsis
  • MDMA, also known as Ecstasy or Molly, has been used since the 1970s for both recreational and therapeutic purposes, with the FDA recognizing its potential for treating PTSD as a Breakthrough Therapy in 2017.
  • The effects of MDMA in therapeutic settings are distinct, promoting trust and self-compassion while allowing cognitive clarity, which differentiates it from other psychedelics.
  • Preliminary evidence indicates that MDMA-Assisted Therapy is effective, with 67%-71% of PTSD patients no longer meeting diagnostic criteria after treatment, significantly more than those receiving placebo therapy.
View Article and Find Full Text PDF
Article Synopsis
  • Cerebral ischemic stroke is a leading cause of disability in adults, and previous studies showed that human Wharton's jelly mesenchymal stromal cells (WJ-MSCs) can help reduce neuronal damage in stroke models.
  • This research explored the effects of WJ-MSC exosomes (Exo) in both cell and rat models of stroke, finding that Exo administration significantly protected neurons from glutamate-induced damage.
  • Rats treated with Exo after a stroke showed improved motor function, reduced brain damage, and increased levels of neuroprotective and anti-apoptotic factors in their brains, indicating that WJ-MSC Exo could be a promising stroke treatment.
View Article and Find Full Text PDF

Maintenance of a central high frequency synapse in the absence of synaptic activity.

Front Cell Neurosci

November 2024

Department of Functional Neuroanatomy, Institute of Anatomy and Cell Biology, Heidelberg University, Heidelberg, Germany.

Activity has long been considered essential for circuit formation and maintenance. This view has recently been challenged by proper synaptogenesis and only mildly affected synapse maintenance in the absence of synaptic activity in forebrain neurons. Here, we investigated whether synaptic activity is necessary for the development and maintenance of the calyx of Held synapse.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!